Fueling Innovation in Biopharma R&D
Our focus and approach to pharma R&D
Despite tremendous advances in scRNA, Omics, and gene data, areas of target biology and chemical spaces still need to be fully understood. Aganitha is a new generation in silico company that integrates high-throughput sciences with deep learning-based generative models to solve complex drug discovery and development challenges. Our approach focuses on deep sciences and deep tech collaboration and includes:
Wet lab augmentation with in silico techniques
Blending in silico techniques with wet lab approaches, using physics-based chemistry and first principles-based systems biology
Disease Focus
Rare Diseases
Advancing therapeutics innovation by researching rare diseases and focusing on treating genetic disorders with advanced gene therapies
CNS (Central Nervous System) Disorders
Immunology Disorders
Oncology
Modalities
Gene and Cell Therapy:
ASO Therapy:
Novel Antibodies:
SMOL & bRo5 molecules:
Mechanism of Action (MoA)
Target identification:
Mechanism of action understanding and validation:
Innovative therapeutic designs:
Targeted delivery:
Optimization of viral capsids etc., allow delivery of the drug payload to cells/tissues/organs with precision. Deep MoA insights allow finer control of next-generation gene therapies, base, prime editors, etc.
Examples of solutions we have developed for our clients
We are committed to developing cutting edge in silico solutions to address complex drug discovery and development challenges. Through our extensive research and development efforts, we have developed methodologies and frameworks for tackling some of the most pressing issues in this field.
Antibody engineering for hard to drug targets
Disease characterization and therapeutic candidates identification and optimization using advanced molecular techniques